These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 27586444)

  • 1. Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys.
    Ciolino JB; Ross AE; Tulsan R; Watts AC; Wang RF; Zurakowski D; Serle JB; Kohane DS
    Ophthalmology; 2016 Oct; 123(10):2085-92. PubMed ID: 27586444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes.
    Serle JB; Podos SM; Kitazawa Y; Wang RF
    Jpn J Ophthalmol; 1998; 42(2):95-100. PubMed ID: 9587840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 15-keto latanoprost on intraocular pressure and aqueous humor dynamics in monkey eyes.
    Wang RF; Gagliuso DJ; Mittag TW; Podos SM
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4143-7. PubMed ID: 17724199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes.
    Gagliuso DJ; Wang RF; Mittag TW; Podos SM
    Arch Ophthalmol; 2004 Sep; 122(9):1342-7. PubMed ID: 15364714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of different dose schedules of latanoprost on intraocular pressure and pupil size in the glaucomatous Beagle.
    Gelatt KN; MacKay EO
    Vet Ophthalmol; 2001 Dec; 4(4):283-8. PubMed ID: 11906665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
    Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pilocarpine 4% in combination with latanoprost 0.005% or 8-iso prostaglandin E2 0.1% on intraocular pressure in laser-induced glaucomatous monkey eyes.
    Serle JB; Wang RF; Mittag TW; Shen F; Podos SM
    J Glaucoma; 2001 Jun; 10(3):215-9. PubMed ID: 11442186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo performance of a drug-eluting contact lens to treat glaucoma for a month.
    Ciolino JB; Stefanescu CF; Ross AE; Salvador-Culla B; Cortez P; Ford EM; Wymbs KA; Sprague SL; Mascoop DR; Rudina SS; Trauger SA; Cade F; Kohane DS
    Biomaterials; 2014 Jan; 35(1):432-9. PubMed ID: 24094935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of latanoprost or 8-iso prostaglandin E2 alone and in combination on intraocular pressure in glaucomatous monkey eyes.
    Wang RF; Podos SM; Serle JB; Mittag TW; Ventosa F; Becker B
    Arch Ophthalmol; 2000 Jan; 118(1):74-7. PubMed ID: 10636418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
    Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes.
    Wang RF; Serle JB; Gagliuso DJ; Podos SM
    J Glaucoma; 2000 Dec; 9(6):458-62. PubMed ID: 11131752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two- and three-times-daily topical ophthalmic application of 0.005% latanoprost solution in clinically normal dogs.
    Tofflemire KL; Whitley EM; Allbaugh RA; Ben-Shlomo G; Robinson CC; Overton TL; Thiessen CE; Evans EA; Griggs AN; Adelman SA; Ludwig AL; Jens JK; Ellinwood NM; Peterson CS; Whitley RD
    Am J Vet Res; 2015 Jul; 76(7):625-31. PubMed ID: 26111092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
    Ge J; Li X; Sun X; He X; Zhang H
    Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension.
    Eveleth D; Starita C; Tressler C
    BMC Ophthalmol; 2012 May; 12():9. PubMed ID: 22607109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
    Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
    Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination.
    Fuwa M; Ueda K; Akaishi T; Yamashita N; Kirihara T; Shimazaki A; Mano H; Kawazu K
    PLoS One; 2016; 11(7):e0158797. PubMed ID: 27383260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation.
    Ota T; Murata H; Sugimoto E; Aihara M; Araie M
    Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2006-11. PubMed ID: 15914616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.
    Maeda-Chubachi T; Chi-Burris K; Simons BD; Freedman SF; Khaw PT; Wirostko B; Yan E;
    Ophthalmology; 2011 Oct; 118(10):2014-21. PubMed ID: 21680022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.
    Takagi Y; Nakajima T; Shimazaki A; Kageyama M; Matsugi T; Matsumura Y; Gabelt BT; Kaufman PL; Hara H
    Exp Eye Res; 2004 Apr; 78(4):767-76. PubMed ID: 15037111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
    Simmons ST; Earl ML;
    Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.